Restricted accessResearch articleFirst published online 2016-05
A Prospective Pharmacogenomic Study of Crohn's Disease Patients during Routine Therapy with Anti-TNF-α Drug Adalimumab: Contribution of ATG5,NFKB1,and CRP Genes to Pharmacodynamic Variability
Crohn's disease is often treated with the anti-tumor necrosis factor-α drug adalimumab. However, about 20%–40% of patients do not display adequate therapeutic response. We prospectively evaluated, during a routine therapy of Crohn's disease patients, the candidate autophagy-related genes ATG12 and ATG5 and the inflammation-related genes NFKB1, NFKBIA, and CRP as potential predictors of adalimumab treatment response (pharmacodynamics). The associations of haplotypes and SNPs in these genes with response to drug therapy, biochemical parameters, and body mass were determined at baseline and after 4, 12, 20, and 30 weeks of therapy. Association analysis showed that haplotypes defined with the SNPs rs9373839 and rs510432 in ATG5 gene were significantly associated with positive response to therapy (p < 0.002). In addition, allele C and genotypes CC and CT of the rs1130864 in the CRP gene were positively associated with therapeutic response (p < 0.002). To the best of our knowledge, this is the first report that supports the association of SNPs in ATG5 and CRP genes with response to adalimumab therapy in Crohn's disease. Further study of these biological pathways in larger and independent clinical samples is warranted as novel streams of research on precision medicine and diagnostics for Crohn's disease.
Get full access to this article
View all access options for this article.
References
1.
AndersenV, ChristensenJ, ErnstA, et al. (2011). Polymorphisms in NF-κB, PXR, LXR, PPARγ and risk of inflammatory bowel disease. World J Gastroenterol, 17, 197–206.
2.
BaertF, MoortgatL, Van AsscheG, et al. (2010). Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology, 138, 463–468.
3.
BankS, AndersenPS, BurischJ, et al. (2014b). Associations between functional polymorphisms in the NF-κB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease. Pharmacogenomics J, 14, 526–534.
4.
BankS, SkyttP, BurischAJ, et al. (2014a). Polymorphisms in the inflammatory pathway genes TLR2, TLR4, TLR9, LY96, NFKBIA, NFKB1, TNFA, TNFRSF1A, IL6R, IL10, IL23R, PTPN22, and PPARG are associated with susceptibility of inflammatory bowel disease in a Danish cohort. PLoS One, 9, 1–10.e98815
5.
Barreiro-de AcostaM, OuburgS, MorreSA, et al. (2010). NOD2, CD14 and TLR4 mutations do not influence response to adalimumab in patients with Crohn's disease: A preliminary report. Revista Españ Enferm Digest, 102, 591–595.
6.
CadwellK., LiuJY, BrownSL, et al. (2008). A key role for autophagy and the autophagy gene ATG16L1 in mouse and human intestinal Paneth cells. Nature, 456, 259–263.
7.
ChenD, ZhuC, WangX, et al. (2013). A novel and functional variant within the ATG5 gene promoter in sporadic Parkinson's disease. Neurosci Lett, 538, 49–53.
8.
ColombelJF, SandbornWJ, RutgeertsP, et al. (2007). Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology, 132, 52–65.
9.
CorreiaCT, AlmeidaJP, SantosPE, et al. (2010). Pharmacogenetics of risperidone therapy in autism: Association analysis of eight candidate genes with drug efficacy and adverse drug reactions. Pharmacogenomics J, 10, 418–430.
10.
DelgadoMA, ElmaouedRA, DavisAS, KyeiG, and DereticV. (2008). Toll-like receptors control autophagy. EMBO J, 27, 1110–1121.
11.
DidebergV, TheatreE, FarnirF, et al. (2006). The TNF/ADAM 17 system: Implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease. Pharmacogenetics Genomics, 16, 727–734.
DubinskyMC, MeiL, FriedmanM, et al. (2010). Genome wide association (GWA) predictors of anti-TNF-α therapeutic responsiveness in pediatric inflammatory bowel disease. Inflamm Bowel Dis, 16, 1357–1366.
14.
DuerrRH, BarmadaMM, ZhangL, PfützerR, and WeeksDE. (2000). High-density genome scan in Crohn's disease shows confirmed linkage to chromosome 14q11–12. Am J Human Genetics, 66, 1857–1862.
15.
European Medicines Agency. Humira (adalimumab), November19, 2014. http://www.ema.europa.eu. Accessed 15Aug2015.
16.
FengX, XiaoJ, LongvilleB, et al. (2009). Complement factor H Y402H and C-reactive protein polymorphism and photodynamic therapy response in age-related macular degeneration. Ophthalmology, 116, 1908–1912.
17.
FujitaN, ItohT, OmoriH, FukudaM, NodaT, and YoshimoriT. (2008). The Atg16L complex specifies the site of LC3 lipidation for membrane biogenesis in autophagy. Mol Biol Cell, 19, 2092–2100.
18.
GutierrezA, ScharlM, SempereL, et al. (2014). Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease. Gut, 63, 272–280.
19.
HanauerSB, SandbornWJ, RutgeertsP, et al. (2006). Human anti-tumour necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC I trial. Gastroenterology, 130, 323–333.
20.
HendersonP, KennedyNA, Van LimbergenJE, et al. (2015). Serum C-reactive protein and CRP genotype in pediatric inflammatory bowel disease: Influence on phenotype, natural history, and response to therapy. Inflamm Bowel Dis, 21, 596–605.
21.
HlavatyT, PersoonsP, VermeireS, et al. (2006). Evaluation of short-term responsiveness and cutoff values of inflammatory bowel disease questionnaire in Crohn's disease. Inflamm Bowel Dis, 12, 199–204.
22.
HlavatyT, PierikM, HenckaertsL, et al. (2005). Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment Pharmacol Ther, 22, 613–626.
23.
HsiehYC, AtharM, and ChaudryIH. (2009). When apoptosis meets autophagy: Deciding cell fate after trauma and sepsis. Trends Mol Med, 15, 129–138.
24.
HuM, LeeMH, MakVW, and TomlinsonB. (2010). Effect of central obesity, low high-density lipoprotein cholesterol and C-reactive protein polymorphisms on C-reactive protein levels during treatment with Rosuvastatin (10 mg daily). Am J Cardiol, 106, 1588–1593.
25.
JostinsL, RipkeS, WeersmaRK, et al. (2012). Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature, 491, 119–124.
26.
JurgensM, JohnJMM, CleynenI, et al. (2011). Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol, 9, 421–427.e1
27.
KaltschmidtB, SparnaT, and KaltschmidtC. (1999). Activation of NF-kappa B by reactive oxygen intermediates in the nervous system. Antioxid Redox Signal, 1, 129–144.
28.
KleinW, TrommA, FolwacznyC, et al. (2004). A polymorphism of the NFKBIA gene is associated with Crohn's disease patients lacking a predisposing allele of the CARD15 gene. Int J Colorectal Dis, 19, 153–156.
29.
KoderS, RepnikK, FerkoljI, et al. (2015). Genetic polymorphism in ATG16L1 gene influences the response to adalimumab in Crohn's disease patients. Pharmacogenomics, 16, 191–204.
30.
LevineB, MizushimaN, and VirginHW. (2011). Autophagy in immunity and inflammation. Nature, 469, 323–335.
31.
LiuJ, PeiY, PapasianCJ, and DengH-W. (2009). Bivariate association analyses for the mixture of continuous and binary traits with the use of extended generalized estimating equations. Genet Epidemiol, 33, 217–227.
32.
MaiuriMC, ZalckvarE, KimchiA, and KroemerG. (2007). Self-eating and self-killing: Crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol, 8, 741–752.
33.
MarquezRT, and XuL. (2012). Bcl-2:Beclin 1 complex: Multiple mechanisms regulating autophagy/apoptosis toggle switch. Am J Cancer Res, 2, 214–221.
34.
MartinLJ, GuptaJ, JyothulaSSSK, et al. (2012). Functional variant in the autophagy-related 5 gene promotor is associated with childhood asthma. PLoS One, 7, e33454.
35.
MayesMD, Bossini-CastilloL, GorlovaO, et al. (2014). Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis. Am J Hum Genet, 94, 47–61.
36.
MugnierM, BalandraudN, DarqueA, RoudierC, RoudierJ, and RevironD. (2003). Polymorphism at position –308 of the tumour necrosis factor-α gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum, 48, 1849–1852.
37.
NedjicJ, AichingerM, EmmerichJ, MizushimaN, and KleinL. (2008). Autophagy in thymic epithelium shapes the T-cell repertoire and is essential for tolerance. Nature, 455, 396–400.
38.
NichitaC, StelleM, VavrickaS, et al. (2010). Clinical experience with adalimumab in a multicenter Swiss cohort of patients with Crohn's disease. Digestion, 81, 78–85.
39.
NimptschK, AleksandrovaK, BoeingH, et al. (2015). Association of CRP genetic variants with blood concentrations of C-reactive protein and colorectal cancer risk. Int J Cancer, 136, 1181–1892.
40.
Peyrin-BirouletL, GonzalezF, DubuquoyL, et al. (2012). Mesenteric fat as a source of C-reactive protein and as a target for bacterial translocation in Crohn's disease. Gut, 61, 78–85.
41.
PierdominiciM, VomeroM, BarbatiC, et al. (2012). Role of autophagy in immunity and autoimmunity, with a special focus on systemic lupus erythematosus. FASEB J, 26, 1400–1412.
42.
Prieto-PérezR, CabaleiroT, DaudénE, and Abad-SantosF. (2013). Gene polymorphisms that can predict response to anti-TNF therapy in patients with psoriasis and related autoimmune diseases. Pharmacogenomics J, 13, 297–305.
43.
ReinischW, WangY, OddensBJ, and LinkR. (2012). C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: A post-hoc analysis from ACCENT I. Aliment Pharmacol Ther, 35, 568–576.
44.
RhodesB, FürnrohrBG, and VyseTJ. (2011). C-reactive protein in rheumatology: Biology and genetics. Nat Rev Rheumatol, 7, 282–289.
45.
RobertsRL, and BarclayML. (2012). Current relevance of pharmacogenetics in immunomodulation treatment for Crohn's disease. J Gastroenterol Hepatol, 27, 1546–1554.
46.
SandbornWJ, HanauerSB, RutgeertsP, et al. (2007b). Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial. Gut, 56, 1232–1239.
47.
SandbornWJ, RutgeertsP, EnnsR, et al. (2007a). Adalimumab induction therapy for Crohn's disease previously treated with infliximab: A randomized trial. Ann Intern Med. 146, 829–838.
48.
SchiotisR, SánchezA, EscuderoA, et al. (2013). Candidate's single-nucleotide polymorphism predictors of treatment nonresponse to the first anti-TNF inhibitor in ankylosing spondylitis. Rheumatol Int, 34, 793–801.
49.
SeufertBL. (2012). Genetic variability in IκBKβ and NFκB1, interactions with NSAID use and risk of colorectal cancer in the Colon Cancer Family Registry. M.S. thesis. University of Washington, USA.
50.
SeufertBL, PooleEM, WhittonJ, et al. (2013). IκBKβ and NFκB1, NSAID use and risk of colorectal cancer in the Colon Cancer Family Registry. Carcinogenesis, 34, 79–85.
51.
ShawRJ, BardeesyN, ManningBD, et al. (2004). The LKB1 tumour suppressor negatively regulates mTOR signaling. Cancer Cell, 6, 91–99.
52.
SinghP, SinghM, NagpalHS, et al. (2014). A novel haplotype within C-reactive protein gene influences CRP levels and coronary heart disease risk in Northwest Indians. Mol Biol Rep, 41, 5851–5862.
53.
SlatteryML, LundgreenA, MullanyLE, et al. (2014). Influence of CHIEF pathway genes on gene expression: A pathway approach to functionality. Int J Mol Epidemiol Genet, 5, 100–111.
54.
SobolewskaA, WłodarczykM, Stec-MichalskaK, et al. (2016). Mean platelet volume in Crohn's disease patients predicts sustained response to a 52-week infliximab therapy: A pilot study. Dig Dis Sci, 61, 542–549.
55.
TersigniR, and PranteraC. (2010). Crohn's Disease: A Multidisciplinary Approach. Springer, Milan, Spain.
56.
ThompsonD, PepysM, and WoodS. (1999). The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure, 7, 169–177.
57.
ToedterGP, BlankM, LangY, ChenD, SandbornWJ, and de VilliersWJ. (2009). Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. Am J Gastroenterol, 104, 2768–2773.
58.
Van DeventerSJ. (1997). Tumour necrosis factor and Crohn's disease. Gut, 40, 443–448.
59.
VermeireS, Van AsscheG, and RutgeertsP. (2006). Laboratory markers in IBD: Useful, magic, or unnecessary toys?. Gut, 55, 426–431.
60.
ZahirF, RabbaniG, Hasan KhanR, RizviSJ, JamalMS, and AbuzenadahAM. (2015). The pharmacological features of bilirubin: The question of the century. Cell Mol Biol Lett, 20, 418–447.
61.
ZegerSL, LiangKY, and AlbertPS. (1988). Models for longitudinal data: A generalized estimating equation approach. Biometrics, 44, 1049–1060.
62.
ZhangH, MasseyDC, and ParkesM. (2014). Expression association analysis of the ATG5, ATG12 and ATG16L1 genes in Crohn's disease (CD) (2014). Gastroenterology, 146, S-876. DOI: 10.1016/S0016-5085(14)63187-5
63.
ZhouXJ, and ZhangH. (2012). Autophagy in immunity: Implications in etiology of autoimmune/autoinflammatory diseases. Autophagy, 8, 1286–1299.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
